Ask a doctor about a prescription for BLENIX 500 mg GASTRO-RESISTANT TABLETS
Package Leaflet: Information for the Patient
Blenix 500 mg Gastro-Resistant Tablets
mesalazine
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Blenix gastro-resistant tabletscontain 500 mg of the active substance mesalazine (also known as 5-aminosalicylic acid), which belongs to a group of medicines called intestinal anti-inflammatory agents.
Blenixis indicated for the treatment of ulcerative colitis, an inflammatory disease of the intestine.
Do not take Claversal
Warnings and precautions
Consult your doctor before starting to take Claversal
If you experience severe or recurrent headache, vision disturbances or ringing or buzzing in the ears, contact your doctor immediately.
In case of appearance of any allergic manifestation (e.g., skin rash, itching) or cramps, abdominal pain, severe headache, and fever during the course of treatment, do not take more tablets and inform your doctor immediately.
Before and during treatment, your doctor may want to perform regular blood and urine tests to check the functioning of your liver, kidneys, blood, and lungs.
Kidney stones may occur with the use of mesalazine. The symptoms include pain in the sides of the abdomen and the presence of blood in the urine. Make sure to drink a sufficient amount of liquid during treatment with mesalazine.
Severe skin rashes, such as drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SSJ), and toxic epidermal necrolysis (TEN), have been observed with mesalazine treatment. Stop taking mesalazine and seek immediate medical attention if you observe any of the symptoms related to these severe skin reactions described in section 4.
Mesalazine may cause a discoloration of the urine to a reddish-brown color after contact with sodium hypochlorite bleach in the toilet water. This is a chemical reaction between mesalazine and bleach and is harmless.
Children and adolescents
Information on safety in the use of this medicine in children and adolescents is limited.
Do not administer to children under 5 years of age.
Other medicines and Claversal 500 mg gastro-resistant tablets
In general, you can continue treatment with other medicines while taking Claversal. However, inform your doctor or pharmacist if you are using, have recently used, or may need to use any other medicine, including those obtained without a prescription.
Claversal may interact with some medicines if taken at the same time.
In particular:
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
There is limited experience with the use of mesalazine during pregnancy and breast-feeding. The newborn may develop allergic reactions after breast-feeding, such as diarrhea. If the newborn develops diarrhea, breast-feeding should be interrupted.
The use of Claversal is not recommended during pregnancy or breast-feeding unless your doctor advises you otherwise.
Driving and using machines
No adverse effects of Claversal on the ability to drive or use machines have been described.
Claversal 500 mg gastro-resistant tablets contain sodium
This medicine contains 49 mg of sodium (main component of cooking/table salt) in each gastro-resistant tablet. This is equivalent to 2.5% of the maximum recommended daily intake of sodium for an adult.
Consult your doctor or pharmacist if you need to take 8 or more gastro-resistant tablets daily for a prolonged period, especially if you have been advised to follow a low-salt diet.
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Your doctor will indicate the duration of your treatment with this medicine. Do not stop treatment before, even if you feel better, as symptoms may return if treatment is stopped too soon.
Strictly follow the treatment according to your doctor's instructions, both in the acute inflammatory phase and in the maintenance time established.
The recommended dose for adults is:
To treat an acute episode of colitis, your doctor will usually prescribe a dose between 1.5 grams (3 gastro-resistant tablets) and 4 grams (8 gastro-resistant tablets) of mesalazine per day, which can be administered once a day or in divided doses.
To help prevent further episodes, your doctor may prescribe a dose between 1.5 grams (3 gastro-resistant tablets) and 3 grams (6 gastro-resistant tablets) of mesalazine per day, which can be administered once a day or in divided doses.
Blenix 500 mg gastro-resistant tablets should be taken orally.
The gastro-resistant tablets should be taken on an empty stomach and should be swallowed whole with the help of liquid. Do not divide, chew, or crush.
Use in children and adolescents
It is not recommended to administerBlenixto children and adolescents due to the lack of data on its safety and efficacy. Do not administer to children under 5 years of age.
Use in elderly patients
The use ofBlenixin elderly patients should be done with caution and limited to those patients with normal renal function.
If you take moreBlenix500 mg gastro-resistant tablets than you should
Consult your doctor if you have taken more than prescribed. In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount taken. It is recommended to take the package and the leaflet of the medicine to the healthcare professional.
If you forget to takeBlenix500 mg gastro-resistant tablets
Do not take a double dose to make up for a forgotten dose.
If you stop takingBlenix500 mg gastro-resistant tablets
It is important that you take Blenixevery day, even when you do not have symptoms of ulcerative colitis. Always finish the treatment that has been prescribed for you.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
All medicines can cause allergic reactions, although serious allergic reactions are very rare. If you get any of the following symptoms after taking this medicine, stop taking this medicine and contact your doctor immediately:
If you experience fever or irritation of the throat or mouth, stop using this medicine and contact your doctor immediately. These symptoms may be due, very rarely, to a decrease in the number of white blood cells in the blood (a condition called agranulocytosis).
Severe side effects:
Stop taking mesalazine and seek immediate medical attention if you experience any of the following symptoms:
The following side effects have also been reported in patients taking mesalazine:
Rare side effects(may affect up to 1 in 1,000 people)
Very rare side effects(may affect less than 1 in 10,000 people)
Side effects of unknown frequency(cannot be estimated from the available data).
severe skin reactions: drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SSJ), and toxic epidermal necrolysis (TEN).
Photosensitivity
More severe reactions have been reported in patients with pre-existing skin conditions, such as atopic dermatitis and atopic eczema.
If these symptoms continue or become more severe, consult your doctor.
Reporting of side effects:
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Monitoring System: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
This medicine does not require any special storage conditions.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date is the last day of the month shown.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition ofBlenix 500 mg gastro-resistant tablets
Appearance of the product and pack contents
Blenixare oblong, orange-colored, gastro-resistant tablets
This medicine is marketed in OPA/Al/PVC//Al blisters packaged in cardboard boxes containing 100 gastro-resistant tablets.
Marketing authorization holder
Faes Farma, S.A.
Autonomia Etorbidea, 10
48940 Leioa (Bizkaia)
Spain
Manufacturer
Faes Farma, S.A.
Maximo Agirre Kalea, 14
48940 Leioa (Bizkaia)
Spain
This medicine is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:
Spain:Blenix 500 mg gastro-resistant tablets
France:Mazalvix 500 mg gastro-resistant tablets
Italy:Salcrozine
Netherlands:Azzavix 500 mg gastro-resistant tablets
Date of last revision of this leaflet: October 2023
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS): http://www.aemps.gob.es/
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for BLENIX 500 mg GASTRO-RESISTANT TABLETS – subject to medical assessment and local rules.